Article
Treatment for SUI may soon be easier to swallow
Chicago-A mixed serotonin and noradrenaline reuptake inhibitor appears to reduce the symptoms associated with stress urinary incontinence (SUI) and improve the quality of life in patients receiving it, according to findings from a phase II clinical trial presented at the American Urogynecologic Society 22nd annual scientific meeting here. While the agent, duloxetine, is still investigational, observers say the prospects for a pharmacologic approach to stress incontinence are promising.
Related Videos
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Alternative treatments and patient communication for genitourinary syndrome of menopause
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
Expert discusses genitourinary syndrome of menopause guidelines
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Urology CNP discusses sensitivity in communication, physical exam
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Urologist discusses drug cost savings, price transparency
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Related Content
April 28th 2025
